Eye disease biotech Ocular Therapeutix about to seal $75M IPO deal

A Bedford biotech firm focused on sustained released treatments for eye diseases, Ocular Therapeutix, is planning to go public this week in a $75 million deal. The offering would be the 13th biotech in the state to hold an IPO since the beginning of the year, an all-time record. Ocular is rare among biotechs looking to go public in that it actually has a product that is approved for use, ReSure Sealant, which is used to close corneal incisions following cataract surgery.

Read the source article at Business News

About the Author

Leave a Reply